Skip to content

To establish an evaluation model of acromegaly disease activity based on doctor-patient co-reporting, and to explore a new model of precision diagnosis and treatment and whole-process management

To establish an evaluation model of acromegaly disease activity based on doctor-patient co-reporting, and to explore a new model of precision diagnosis and treatment and whole-process management

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2400090129
Enrollment
Unknown
Registered
2024-09-24
Start date
2024-10-01
Completion date
Unknown
Last updated
2024-09-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acromegaly

Interventions

Biochemical unremission group:NA
Biochemical remission group:NA
Discordance between GH and IGF-1 group:NA

Sponsors

Peking Union Medical College Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
10 Years to 99 Years

Inclusion criteria

Inclusion criteria: (1) There is no age limit for the subjects. (2) The diagnostic criteria for acromegaly were met: GH valley value of glucose GH inhibition test =1.0 ng/ml: IGF-1 exceeded the reference range of the same age and sex [> 1.0 upper multiple of the normal range (ULN)]; MRI or CT in the sellar area suggests pituitary adenoma. (3) Complete clinical data at the time of diagnosis, receive treatment in our hospital, and agree to regular review and follow-up as required. (4) Sign informed consent.

Exclusion criteria

Exclusion criteria: (1) The diagnosis is not consistent with acromegaly. (2) The clinical data and specific treatment plan of the newly diagnosed patients in other hospitals are incomplete at the diagnosis baseline. (3) Failure to perform regular examinations and follow-up visits as required. (4) Failure to provide personal health information and quality of life scores as required by follow-up. (5) Combined with other critical diseases, life expectancy is shorter.

Design outcomes

Primary

MeasureTime frame
Growth hormone;Insulin-like growth factor 1;Pituitary MRI;Clinical symptoms;Complications;Quality of life scores;

Countries

China

Contacts

Public ContactDuan Lian

Peking Union Medical College Hospital

duanlianpumc@163.com+86 136 7135 5817

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026